REG - Aptamer Group PLC - Aptamer Announces New Data at ASGCT

AptamerAnnouncement

15/05/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250515:nRSO7353Ia&default-theme=true

RNS Number : 7353I  Aptamer Group PLC  15 May 2025

 

15 May 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Aptamer Announces New Data at ASGCT

Optimer delivery vehicle supports expansion across high-value fibrotic
indications

 

Aptamer Group plc (AIM: APTA), the leading developer of next-generation
synthetic binders delivering innovation to the life science industry, today
announces new data on its Optimer therapeutic delivery vehicle for liver
fibrosis. The data, developed through Aptamer's internal programme and in
collaboration with AstraZeneca, highlight the delivery platform's potential
for broad therapeutic application.

 

The latest results presented at the American Society of Gene and Cell Therapy
(ASGCT) Annual Meeting in New Orleans, LA (13-17 May 2025) show the Optimer
targets fibrosis in multiple tissue types and is compatible with mouse and rat
animal models, which makes the transition to preclinical animal studies a
simpler and faster next step.

 

Recent in-house studies have shown that the Optimer effectively targets
fibrosis in the liver as well as the kidney, skin, lung, and heart. These
findings position the asset as a highly adaptable therapeutic delivery system
with broad applicability across fibrotic diseases.

 

This represents a significant step forward in unlocking multi-billion-dollar
opportunities in areas of high unmet medical need. The delivery vehicle had
previously shown the ability to deliver three different siRNA molecules,
demonstrating compatibility with different therapeutic cargos. The ability to
combine different therapeutic cargos with targeting to different tissues means
this asset could act as a platform for the development of a range of precision
therapies.

 

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, said: "These
results broaden the scope of Aptamer's internal development programme,
indicating our asset could address a broad range of disease areas. While
fibrotic liver disease remains a major focus due to its large market size and
limited treatment options, the potential to expand into pulmonary, renal,
cardiac, and dermal fibrosis greatly increases the commercial scope of this
delivery system.

 

"With the market for liver fibrosis treatments set to grow at a compound
annual growth rate of 24% through 2035, driven by new drugs under development
and rising disease prevalence,(1) the Group is well-positioned to capitalise
on this momentum. Aptamer's ongoing collaboration with AstraZeneca continues
to generate compelling data, and multiple pharmaceutical companies have
initiated discussions to explore partnerships over the next few months."

 

1.    Delveinsight. Liver Fibrosis Market Insight, Epidemiology And Market
Forecast - 2034. (2025)

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Dr Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott / Jade Bayat 
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 James Pope / Andrew Thacker 
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group

Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group
develops Optimer® binders, advanced molecules that work like antibodies by
attaching to specific targets in the body. These binders are used
in medicine, diagnostic tests, and research tools, offering benefits
like high stability, reliable performance, and lower costs compared to
traditional antibodies.

 

Aptamer operates a fee-for-service business in the $210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners,
aiming for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESSFDEELEISEFI